Suppression of stent-induced tissue hyperplasia in rats by using small interfering RNA to target matrix metalloproteinase-9

Background and study aims: We evaluated the efficacy of small interfering RNA (siRNA) in targeting matrix metalloproteinase (MMP-9) to suppress stent-induced tissue hyperplasia in a rat esophageal model.

Methods: The silencing effect of the candidate siRNA (termed (MMP-9 siRNA) was evaluated in 9 L rat glial cells. Four groups of rats (n = 10, each group) were used: Eso-S, stent insertion only, comparison; Eso-R, stent insertion plus treatment with MMP-9 siRNA complexed with Chol-R9 for delivery, experimental; Eso-P, stent insertion plus treatment with pCMV-luc complexed with Chol-R9, for confirmation of Chol-R9 delivery effect; and Eso-N, no stent insertion and no treatment, controls. All rats were sacrificed at 3 weeks. The therapeutic efficacy of the MMP-9 siRNA/Chol-R9 complex was assessed.

Results: The most potent MMP-9 siRNA was selected. Compared with the Eso-S group, the Eso-R group showed significantly less tissue hyperplasia with a lower percentage of granulation tissue and smaller granulation tissue area, and also significantly lower MMP-9 level.

Conclusions: MMP-9 siRNA/Chol-R9 is effective for inhibiting stent-induced tissue hyperplasia in a rat esophageal model.

• References

• 1 Repici A, Conio M, De Angelis C et al. Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc 2004; 60: 513-519
• 2 Shin JH, Song HY, Ko GY et al. Esophagorespiratory fistula: long-term results of palliative treatment with covered expandable metallic stents in 61 patients. Radiology 2004; 232: 252-259
• 3 Song HY, Park SI, Do YS et al. Expandable metallic stent placement in patients with benign esophageal strictures: results of long-term follow-up. Radiology 1997; 203: 131-136
• 4 Chen JS, Luh SP, Lee F et al. Use of esophagectomy to treat recurrent hyperplastic tissue obstruction caused by multiple metallic stent insertion for corrosive stricture. Endoscopy 2000; 32: 542-545
• 5 Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262
• 6 Shin JH, Sung KB, Kim EY et al. A rat tracheal model to investigate stent-induced tissue hyperplasia: a pilot study. J Vasc Interv Radiol 2010; 21: 1878-1883
• 7 Jones GT, Kay IP, Chu JW et al. Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 2006; 26: e121-125
• 8 Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-184
• 9 Shan G, Li Y, Zhang J et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008; 26: 933-940
• 10 Kim WJ, Kim SW. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 2009; 26: 657-666
• 11 Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council. Earth and Life studies. Washington DC: National Academy Press; 1996
• 12 Kim EY, Shin JH, Jung YY et al. A rat esophageal model to investigate stent-induced tissue hyperplasia. J Vasc Interv Radiol 2010; 21: 1287-1291
• 13 Schmid RM, Weidenbach H, Draenert GF et al. Liposome mediated gene transfer into the rat oesophagus. Gut 1997; 41: 549-556
• 14 Manthorpe M, Cornefert-Jensen F, Hartikka J et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther 1993; 4: 419-431
• 15 Jo Chae K, Rha SY, Oh BK et al. Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma. Am J Gastroenterol 2004; 99: 68-75